Nitrazepam Accord Healthcare

Nitrazepam, the active ingredient in Nitrazepam Accord Healthcare, is a benzodiazepine presented as a tablet for oral use. It is used to manage insomnia, severe anxiety, and certain seizure disorders in adults. GNH USA supplies Nitrazepam Accord Healthcare as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitrazepam is a benzodiazepine that acts on the central nervous system to produce sedative and anticonvulsant effects. - Insomnia: helps initiate and maintain sleep in adults with difficulty sleeping. - Severe anxiety: reduces excessive anxiety symptoms in patients requiring short‑term relief. - Epileptic seizures: provides adjunctive control of certain seizure types, particularly in refractory cases.

Nitrazepam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dizziness: sensation of light‑headedness or unsteadiness. - Impaired coordination: reduced motor control and balance. - Memory impairment: difficulty recalling recent events.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Depression or suicidal thoughts: mood changes requiring immediate medical attention. - Withdrawal seizures: risk of seizures if the drug is stopped abruptly after prolonged use.

When prescribing Nitrazepam, clinicians should consider several safety measures. - Dose adjustment in elderly: start with the lowest effective dose due to increased sensitivity. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal. - Use with caution in hepatic impairment: monitor liver function regularly. - Avoid concurrent CNS depressants: increased risk of excessive sedation. - Store at room temperature: keep in the original pack, protect from moisture and light.

Nitrazepam can interact with a variety of medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Opioids: additive respiratory depression may be life‑threatening. - Alcohol: profound sedation and increased risk of overdose. - Other benzodiazepines: excessive sedation and dependence. - Antidepressants (TCAs, MAOIs): heightened central nervous system depression.

Moderate Interactions (Monitor Closely): - Anticonvulsants (phenytoin, carbamazepine): may reduce nitrazepam plasma levels. - CYP3A4 inhibitors (ketoconazole, erythromycin): can increase nitrazepam exposure. - CYP3A4 inducers (rifampicin, carbamazepine): may decrease efficacy.